Teva is optimistic of launching it and partner MedinCell’s proposed 505(b)(2) hybrid risperidone long-acting injectable product in the US by 1 July 2023, after completing re-submission of the firm’s new drug application with the US Food and Drug Administration.
Seven months ago, the US agency issued Teva a complete response letter rejecting approval for the NDA in its existing...








